Zoetis stock rises despite disappointing earnings guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2024
0mins
Should l Buy ZTS?
Source: WSJ
Zoetis Inc's stock rose by 5.01% as it crossed above the 5-day SMA, indicating a potential recovery phase. However, the company recently reported a decline in Q1 earnings, which fell short of expectations, and lowered its full-year EPS and revenue guidance, reflecting challenges in the pet care market as pet owners reduce vet visits due to price pressures. This situation has led to Zoetis being highlighted on the oversold list, suggesting that while the stock is experiencing a short-term uptick, the underlying fundamentals remain concerning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 74.220
Low
130.00
Averages
154.20
High
200.00
Current: 74.220
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Earnings Season Volatility Hits US Stocks
- Strong Earnings Season: As the earnings season progresses, the S&P 500 reached an intraday record high of 7,501.24 on Thursday, reflecting strong investor confidence in corporate earnings, although it pulled back on Friday due to declines in tech stocks.
- Cisco's Stock Surge: Cisco shares soared 22% in one week following better-than-expected fiscal Q3 results, with a relative strength index (RSI) of 90 indicating the stock is in overbought territory, suggesting a potential short-term pullback risk.
- Zoetis Decline: Zoetis topped the oversold list with a 10% drop in the past week and an RSI of 14.4, as its Q1 earnings fell short of expectations and it lowered full-year EPS and revenue guidance, indicating pet owners are cutting back on vet visits due to price pressures.
- Market Sentiment Fluctuations: Despite strong performances from stocks like Cisco, the overall market experienced volatility due to disappointment over the U.S.-China summit outcomes, prompting investors to watch for potential rebounds in overbought and oversold stocks.
See More
Semiconductor Stocks Surge, Defensive Stocks Under Pressure
- Semiconductor Stocks Shine: Companies like Intel, Micron, and Seagate have surged over 40% in 2026, significantly exceeding their 200-day moving averages, indicating a robust momentum driven by AI and data center trades that are reshaping market dynamics.
- Storage Companies Benefit: Firms such as Seagate and Western Digital are favored by investors due to rising demand for memory and data infrastructure, further solidifying their market positions and reflecting a sustained preference for tech stocks.
- Defensive Stocks Under Pressure: Defensive consumer and healthcare stocks like Zoetis and Abbott are trading significantly below their long-term trends, illustrating a shift in investor preference towards high-beta tech stocks, resulting in severe overselling of these names.
- Cautious Sentiment in Software Sector: IT services and enterprise software companies, including Accenture and ServiceNow, feature prominently on the oversold list, indicating investor caution regarding the software trade amid slowing corporate spending and potential long-term disruptions from generative AI tools.
See More
Memory Chip Stocks Surge but Face Potential Decline
- Memory ETF Surge: The Roundhill Memory ETF (DRAM) surged nearly 30% this week, reflecting strong performance in memory chip and data storage stocks driven by AI trades, despite modest overall market gains.
- Outstanding Individual Stocks: Qualcomm rose over 23% this week, while Micron soared nearly 37%, marking its best weekly performance since 2008; however, both stocks have relative strength indices (RSI) exceeding 80, indicating potential pullback risks.
- Overbought and Oversold Dynamics: Qualcomm's RSI stands at 86, with a consensus hold rating among analysts, predicting a 22% drop to reach the price target, while Micron's RSI is at 82, rated buy by most analysts, yet still has a 23% downside potential.
- EPAM and Zoetis Under Pressure: EPAM Systems has an RSI of 18 after falling over 11% due to a revenue growth outlook cut, while Zoetis dropped more than 27% after missing first-quarter earnings expectations, with an RSI close to 15, indicating strong oversold signals.
See More
Healthcare Stocks Decline Late Friday Afternoon
- Healthcare Sector Decline: Late Friday afternoon, the NYSE Healthcare Index experienced a decline, indicating a weakening market confidence in the healthcare sector, which may affect investors' short-term decisions.
- Market Sentiment Deterioration: The widespread drop in healthcare stocks could lead investors to reassess their portfolios in the healthcare sector, resulting in increased capital outflows and heightened market volatility.
- Significant Industry Impact: The decline in healthcare stocks may trigger a ripple effect on related companies' stock prices, impacting their financing capabilities and future growth expectations, especially in the current uncertain economic environment.
- Investor Focus Shift: As healthcare stocks weaken, investors may redirect their attention to other sectors in search of more attractive investment opportunities, potentially affecting capital inflows into the healthcare industry.
See More
US Stocks Close Lower Amid Cautious Market Sentiment
- Market Weakness: On Thursday, the S&P 500 Index fell by 0.38%, the Dow Jones Industrial Average dropped by 0.63%, and the Nasdaq 100 Index decreased by 0.12%, reflecting investor skepticism regarding a potential US-Iran peace deal, which led to a reversal of early gains and impacted market confidence.
- Economic Data Support: Despite the market decline, initial jobless claims rose by 10,000 to 200,000, below the expected 205,000, indicating resilience in the labor market, while Q1 nonfarm productivity increased by 0.8%, surpassing the 0.6% forecast, providing some support to the market.
- Earnings Report Impact: As of Thursday, 84% of the 425 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, although growth outside the tech sector is only expected to be around 3%, indicating a divergence that may influence investor allocation strategies.
- Oil Price Recovery: WTI crude oil prices rebounded after a 4% decline on Thursday, as the market focused on the potential resumption of US military operations to ensure safe passage through the Strait of Hormuz, which is expected to have ongoing implications for global oil prices and related stocks.
See More
Zoetis Q1 2026 Earnings Call Insights
- Flat Revenue Performance: Zoetis reported global revenue of $2.3 billion for Q1 2026, with a 3% reported growth but flat organic operational revenue, indicating signs of weakened market demand, particularly in the companion animal segment.
- International Growth: The international segment achieved 10% organic operational revenue growth, while the U.S. market declined by 8%, suggesting an uneven performance across global markets that may impact future strategic positioning.
- Acquisition to Expand Capabilities: Zoetis announced the acquisition of Neogen's animal genomics business, aimed at enhancing its capabilities in livestock genetics, which could provide new growth avenues amid a competitive market landscape.
- Revised Earnings Outlook: The company has lowered its 2026 revenue guidance to a range of $9.68 billion to $9.96 billion, expecting organic operational revenue growth of 2% to 5%, reflecting the response to uncertainties and competitive pressures in the market.
See More
Earnings Season Volatility Hits US Stocks
- Strong Earnings Season: As the earnings season progresses, the S&P 500 reached an intraday record high of 7,501.24 on Thursday, reflecting strong investor confidence in corporate earnings, although it pulled back on Friday due to declines in tech stocks.
- Cisco's Stock Surge: Cisco shares soared 22% in one week following better-than-expected fiscal Q3 results, with a relative strength index (RSI) of 90 indicating the stock is in overbought territory, suggesting a potential short-term pullback risk.
- Zoetis Decline: Zoetis topped the oversold list with a 10% drop in the past week and an RSI of 14.4, as its Q1 earnings fell short of expectations and it lowered full-year EPS and revenue guidance, indicating pet owners are cutting back on vet visits due to price pressures.
- Market Sentiment Fluctuations: Despite strong performances from stocks like Cisco, the overall market experienced volatility due to disappointment over the U.S.-China summit outcomes, prompting investors to watch for potential rebounds in overbought and oversold stocks.
See More
Semiconductor Stocks Surge, Defensive Stocks Under Pressure
- Semiconductor Stocks Shine: Companies like Intel, Micron, and Seagate have surged over 40% in 2026, significantly exceeding their 200-day moving averages, indicating a robust momentum driven by AI and data center trades that are reshaping market dynamics.
- Storage Companies Benefit: Firms such as Seagate and Western Digital are favored by investors due to rising demand for memory and data infrastructure, further solidifying their market positions and reflecting a sustained preference for tech stocks.
- Defensive Stocks Under Pressure: Defensive consumer and healthcare stocks like Zoetis and Abbott are trading significantly below their long-term trends, illustrating a shift in investor preference towards high-beta tech stocks, resulting in severe overselling of these names.
- Cautious Sentiment in Software Sector: IT services and enterprise software companies, including Accenture and ServiceNow, feature prominently on the oversold list, indicating investor caution regarding the software trade amid slowing corporate spending and potential long-term disruptions from generative AI tools.
See More
Memory Chip Stocks Surge but Face Potential Decline
- Memory ETF Surge: The Roundhill Memory ETF (DRAM) surged nearly 30% this week, reflecting strong performance in memory chip and data storage stocks driven by AI trades, despite modest overall market gains.
- Outstanding Individual Stocks: Qualcomm rose over 23% this week, while Micron soared nearly 37%, marking its best weekly performance since 2008; however, both stocks have relative strength indices (RSI) exceeding 80, indicating potential pullback risks.
- Overbought and Oversold Dynamics: Qualcomm's RSI stands at 86, with a consensus hold rating among analysts, predicting a 22% drop to reach the price target, while Micron's RSI is at 82, rated buy by most analysts, yet still has a 23% downside potential.
- EPAM and Zoetis Under Pressure: EPAM Systems has an RSI of 18 after falling over 11% due to a revenue growth outlook cut, while Zoetis dropped more than 27% after missing first-quarter earnings expectations, with an RSI close to 15, indicating strong oversold signals.
See More
Healthcare Stocks Decline Late Friday Afternoon
- Healthcare Sector Decline: Late Friday afternoon, the NYSE Healthcare Index experienced a decline, indicating a weakening market confidence in the healthcare sector, which may affect investors' short-term decisions.
- Market Sentiment Deterioration: The widespread drop in healthcare stocks could lead investors to reassess their portfolios in the healthcare sector, resulting in increased capital outflows and heightened market volatility.
- Significant Industry Impact: The decline in healthcare stocks may trigger a ripple effect on related companies' stock prices, impacting their financing capabilities and future growth expectations, especially in the current uncertain economic environment.
- Investor Focus Shift: As healthcare stocks weaken, investors may redirect their attention to other sectors in search of more attractive investment opportunities, potentially affecting capital inflows into the healthcare industry.
See More
US Stocks Close Lower Amid Cautious Market Sentiment
- Market Weakness: On Thursday, the S&P 500 Index fell by 0.38%, the Dow Jones Industrial Average dropped by 0.63%, and the Nasdaq 100 Index decreased by 0.12%, reflecting investor skepticism regarding a potential US-Iran peace deal, which led to a reversal of early gains and impacted market confidence.
- Economic Data Support: Despite the market decline, initial jobless claims rose by 10,000 to 200,000, below the expected 205,000, indicating resilience in the labor market, while Q1 nonfarm productivity increased by 0.8%, surpassing the 0.6% forecast, providing some support to the market.
- Earnings Report Impact: As of Thursday, 84% of the 425 S&P 500 companies that reported earnings exceeded expectations, with Q1 earnings projected to rise by 12% year-over-year, although growth outside the tech sector is only expected to be around 3%, indicating a divergence that may influence investor allocation strategies.
- Oil Price Recovery: WTI crude oil prices rebounded after a 4% decline on Thursday, as the market focused on the potential resumption of US military operations to ensure safe passage through the Strait of Hormuz, which is expected to have ongoing implications for global oil prices and related stocks.
See More
Zoetis Q1 2026 Earnings Call Insights
- Flat Revenue Performance: Zoetis reported global revenue of $2.3 billion for Q1 2026, with a 3% reported growth but flat organic operational revenue, indicating signs of weakened market demand, particularly in the companion animal segment.
- International Growth: The international segment achieved 10% organic operational revenue growth, while the U.S. market declined by 8%, suggesting an uneven performance across global markets that may impact future strategic positioning.
- Acquisition to Expand Capabilities: Zoetis announced the acquisition of Neogen's animal genomics business, aimed at enhancing its capabilities in livestock genetics, which could provide new growth avenues amid a competitive market landscape.
- Revised Earnings Outlook: The company has lowered its 2026 revenue guidance to a range of $9.68 billion to $9.96 billion, expecting organic operational revenue growth of 2% to 5%, reflecting the response to uncertainties and competitive pressures in the market.
See More
